Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzNbmJKSzVyPUWuPFY3PiEQvF2= M{nOZnNCVkeHUh?=
DOHH-2 M3S3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXpTldRUUN3ME25MlM2Pjh7IN88US=> MnX1V2FPT0WU
no-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:3NHpHUUN3ME25MlkxOzlizszN M{HRXHNCVkeHUh?=
LS-513 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G4UmlEPTB;MUGuN|U1PyEQvF2= Ml:wV2FPT0WU
ALL-PO NVrYcFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr6RmdKSzVyPUGxMlc4OzRizszN M2\lbnNCVkeHUh?=
8-MG-BA MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHmdo9KSzVyPUGzMlEyOjNizszN NHrsbHhUSU6JRWK=
RPMI-8402 NVmxfWllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\VZm9HUUN3ME2xOU45PTN5IN88US=> NU\XXoxFW0GQR1XS
EoL-1-cell M2\VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD1zOD61PVQ5KM7:TR?= NH[2XIRUSU6JRWK=
NALM-6 M13Mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGyTWM2OD1zOT6wNVY4KM7:TR?= MmiwV2FPT0WU
DEL M3joc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uwXmlEPTB;MkCuNVQ4OSEQvF2= MWXTRW5ITVJ?
SR NVnjPXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3XNXdDUUN3ME2yN{43PzF3IN88US=> M4PxSnNCVkeHUh?=
697 NUDSNI5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zqbmlEPTB;Mk[uOlE2PSEQvF2= MojvV2FPT0WU
COLO-829 NV\4UpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7ueZpCUUN3ME2yOk45PDh|IN88US=> MkD4V2FPT0WU
EVSA-T NIfDNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvR[oJJUUN3ME2yO{42PTZzIN88US=> MVjTRW5ITVJ?
ATN-1 NEfKR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTHTmFKSzVyPUOxMlI{OjlizszN NUL6N204W0GQR1XS
L-363 M37FS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojJTWM2OD1|MT63OFYyKM7:TR?= MW\TRW5ITVJ?
LAMA-84 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN{LkWyNVEh|ryP NUHDN4k3W0GQR1XS
NOS-1 M1XRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN2LkK5OVYh|ryP M1O3ZXNCVkeHUh?=
BB30-HNC NVPBcIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf2N5NKSzVyPUO0MlM{ODZizszN MmfZV2FPT0WU
BC-1 NXy4fXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrPTWM2OD1|Nz65O|Q3KM7:TR?= MlLlV2FPT0WU
IST-SL2 NI\HVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\oPZNKSzVyPUO4MlIzPCEQvF2= MWjTRW5ITVJ?
D-392MG Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3iSHJ2UUN3ME20NE4zOjF3IN88US=> M13BVHNCVkeHUh?=
no-11 M3Wxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7GTWM2OD12MD61OVIyKM7:TR?= NF[3ellUSU6JRWK=
LC4-1 M1GwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRyLki3NVYh|ryP MVTTRW5ITVJ?
A388 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e0W2lEPTB;NEKuOVg1QCEQvF2= NILWNpRUSU6JRWK=
NTERA-S-cl-D1 M376W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTR{LkewO|Qh|ryP M4njenNCVkeHUh?=
CESS NUXLWIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nlU2lEPTB;NESuNlI{OiEQvF2= MoXyV2FPT0WU
RS4-11 M3PBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfadXpGUUN3ME20PU4xQTN6IN88US=> NULPO|ZKW0GQR1XS
MS-1 NFnvZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT5SGxKSzVyPUWwMlk{PTFizszN MnTLV2FPT0WU
CTV-1 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD13MT6wO|Qh|ryP MkfxV2FPT0WU
D-502MG Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qTmlEPTB;NUGuOlI4OSEQvF2= Ml[5V2FPT0WU
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X1dmlEPTB;NUKuPVE6PSEQvF2= MWrTRW5ITVJ?
SK-NEP-1 NYjneWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0fZNkUUN3ME21N{4{QTJ|IN88US=> M2L5fXNCVkeHUh?=
LOXIMVI MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP5Z3JKSzVyPUWzMlU5QDRizszN NFzFRYFUSU6JRWK=
DJM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfmRYlKSzVyPUW2MlM{QTFizszN MYfTRW5ITVJ?
GI-1 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD13Nj62NVQ6KM7:TR?= NF3leZpUSU6JRWK=
IST-MES1 M1LNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET6TZJKSzVyPU[wMlU1QTNizszN NVLVWpRlW0GQR1XS
MV-4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZyLk[1N|gh|ryP NWm4UJlMW0GQR1XS
OVCAR-4 M4CyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPiSoVPUUN3ME22N{42PjV5IN88US=> NFjIPGFUSU6JRWK=
KE-37 M3;5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[0NmlEPTB;Nk[uNlY3QCEQvF2= MkLLV2FPT0WU
D-542MG MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZ6LkSxN|Uh|ryP M3G2TXNCVkeHUh?=
MHH-PREB-1 NXvvNIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTd{Lki0OFEh|ryP MmXiV2FPT0WU
MRK-nu-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTd|LkS3NFUh|ryP NGKzV5VUSU6JRWK=
D-247MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH0fnFKSzVyPUezMlU1PDJizszN MXPTRW5ITVJ?
OCI-AML2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFezXYpKSzVyPUe2Mlk{PjlizszN M1jLOnNCVkeHUh?=
LP-1 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPSW5FKSzVyPUiyMlg4OzFizszN MkG0V2FPT0WU
HCC1599 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HIU2lEPTB;OESuNlg{PyEQvF2= NWjaOIRbW0GQR1XS
KARPAS-45 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHhc5pKSzVyPUi0MlY6QTJizszN MVzTRW5ITVJ?
BE-13 NITXZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHZTWM2OD17OT6wOFc4KM7:TR?= MkX2V2FPT0WU
GCIY MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTl7LkC5OVQh|ryP NYDY[FM6W0GQR1XS
BV-173 NGLRSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W2U2lEPTB;MUCwMlMzPSEQvF2= M1rYfHNCVkeHUh?=
LB2518-MEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kOWlEPTB;MUCwMlc5QSEQvF2= NWH2em04W0GQR1XS
KS-1 NGjqdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFyMT62N|kh|ryP NEjme41USU6JRWK=
MOLT-16 NX72SW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0SlQ{UUN3ME2xNFQvQTh4IN88US=> MXvTRW5ITVJ?
NCI-H1770 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVZVFqUUN3ME2xNFgvPzh2IN88US=> MoewV2FPT0WU
NCI-H82 M33pVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\h[2lEPTB;MUGwMlk4PiEQvF2= NUHXb|N2W0GQR1XS
NCCIT MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf3bYtkUUN3ME2xNVIvPTJ7IN88US=> MnW2V2FPT0WU
KALS-1 NH3sXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzNT65OFEh|ryP NWKw[VY2W0GQR1XS
LB2241-RCC NVXQT3BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETHXHNKSzVyPUGxOk43PzlizszN Mn:wV2FPT0WU
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jWfGlEPTB;MUG3MlM6PSEQvF2= MVnTRW5ITVJ?
HD-MY-Z M{Phdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzOD60PFgh|ryP NHfP[3NUSU6JRWK=
EB-3 NFnGfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH2WGpKSzVyPUGyN{4xQTRizszN MlHFV2FPT0WU
BL-70 M4jKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\2TWM2OD1zMkOuNVI4KM7:TR?= M1e5V3NCVkeHUh?=
K-562 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvPSWNKSzVyPUGyOk4zPDVizszN NFH3RmZUSU6JRWK=
HT-144 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF|Mz6xOlQh|ryP MlXFV2FPT0WU
PF-382 M1TMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF|ND6zOlEh|ryP MoPPV2FPT0WU
RPMI-8226 NIT6R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF|NT6wOFUh|ryP MXXTRW5ITVJ?
NCI-H1355 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzvcZFVUUN3ME2xN|UvPTh5IN88US=> M33RfnNCVkeHUh?=
LXF-289 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXaTWM2OD1zM{muO|gyKM7:TR?= MWrTRW5ITVJ?
NCI-H69 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi4clg6UUN3ME2xOFIvQTN{IN88US=> Mm\BV2FPT0WU
SK-MEL-1 NIjjdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPoTWM2OD1zNEeuNVMh|ryP MYDTRW5ITVJ?
KARPAS-299 NFe1ZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD1zNEmuNVIh|ryP NYn5PZljW0GQR1XS
GB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW2TWM2OD1zNEmuN|IzKM7:TR?= MY\TRW5ITVJ?
CMK M1jxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXxTWM2OD1zNEmuOVE2KM7:TR?= NGWxT4RUSU6JRWK=
MPP-89 NUDPb3poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfCdno6UUN3ME2xOVYvODN3IN88US=> MkC4V2FPT0WU
KU812 NVH1cWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3oTWM2OD1zNkGuPVAzKM7:TR?= NFjDUHVUSU6JRWK=
REH MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBfWlEPTB;MU[yMlEzPSEQvF2= NGjrclJUSU6JRWK=
NEC8 NY\weIZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGzVJlKSzVyPUG2OU4xOjZizszN M2P2RXNCVkeHUh?=
KP-N-YS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF4OD6zPVUh|ryP MkTSV2FPT0WU
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PQWWlEPTB;MU[5MlkyPSEQvF2= MmjlV2FPT0WU
Becker NFLFXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2[nVKSzVyPUG3OE4yQCEQvF2= M{HsfHNCVkeHUh?=
LB647-SCLC MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33CVmlEPTB;MUe1Mlg1PSEQvF2= NVvER5NOW0GQR1XS
LU-139 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrEU4R4UUN3ME2xO|gvODF7IN88US=> NHv4OlRUSU6JRWK=
QIMR-WIL M1fm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\lOlZKSzVyPUG3PU43PDZizszN M1HTUHNCVkeHUh?=
NCI-H1395 NFv1OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;sTWM2OD1zN{muPVk3KM7:TR?= NHj3W|hUSU6JRWK=
NOMO-1 M3\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PRd2lEPTB;MUiyMlg2KM7:TR?= M{Dye3NCVkeHUh?=
GI-ME-N NX3ZRpVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTFe|I3UUN3ME2xPFcvQTZ7IN88US=> M2[xTnNCVkeHUh?=
KMS-12-PE MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqyTWM2OD1zOEmuNlc{KM7:TR?= NXHGTZlVW0GQR1XS
Daudi MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333cmlEPTB;MUmxMlEzQCEQvF2= NUDmdYt6W0GQR1XS
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF7MT62PVkh|ryP Mn3jV2FPT0WU
NCI-H2107 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;vTWM2OD1zOUOuO|M6KM7:TR?= MXfTRW5ITVJ?
SK-PN-DW MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF7ND63NVkh|ryP NXjZdlhiW0GQR1XS
MC-CAR NWrp[olIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT0XGZKSzVyPUKwNk4zPTNizszN MWnTRW5ITVJ?
SNB75 NWDLdGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW3XGJqUUN3ME2yNlEvQTRizszN NUXUbpY2W0GQR1XS
ES4 NIjUN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrlNGhZUUN3ME2yNlMvPzh|IN88US=> M333d3NCVkeHUh?=
KARPAS-422 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ZN4tkUUN3ME2yNlgvOzV{IN88US=> NWTR[G5sW0GQR1XS
NCI-H1648 M17U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfxV4dKSzVyPUKyPU41QDlizszN NVnqe2d6W0GQR1XS
ES6 NV3xW2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ|OT60N{DPxE1? NVfhfnFLW0GQR1XS
KNS-81-FD M2HSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrpSJlKSzVyPUK0NU4yQTdizszN MnXNV2FPT0WU
JAR MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD1{NU[uNlI2KM7:TR?= NGr6N5JUSU6JRWK=
NB1 M3n4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDFTWM2OD1{NkCuOVE3KM7:TR?= Mni3V2FPT0WU
D-336MG NW[xSXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rzOWlEPTB;Mk[wMlY6QCEQvF2= M1u5[3NCVkeHUh?=
BC-3 NFGwd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTPfJBKSzVyPUK2OU4yPzhizszN NHTxVHBUSU6JRWK=
HCC2218 NFK3PXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5XnFuUUN3ME2yOlYvPDF3IN88US=> Mmf5V2FPT0WU
TE-9 MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[0fFRjUUN3ME2yOlYvPjJ5IN88US=> MV;TRW5ITVJ?
LB1047-RCC M1HQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezcWlEPTB;Mk[2Mlc2OyEQvF2= MmfrV2FPT0WU
CTB-1 NFvETYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj1dW9KSzVyPUK2PU46PzNizszN M{L6OHNCVkeHUh?=
NB7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ5MTFOwG0> NF\ye5ZUSU6JRWK=
ST486 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rtWWlEPTB;Mke3MlQyOiEQvF2= M{\W[3NCVkeHUh?=
HCC1187 M37kOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K2W2lEPTB;MkiyMlgyOSEQvF2= MWrTRW5ITVJ?
NCI-SNU-16 NFXhcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHtTWM2OD1{OESuNlQ5KM7:TR?= NFTReFdUSU6JRWK=
COR-L279 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnnW29KSzVyPUK5NU42QDRizszN NWexd|RZW0GQR1XS
ES8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne2TWM2OD1{OUSuNVgzKM7:TR?= MoPHV2FPT0WU
U-698-M M4HaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfoflJKSzVyPUK5PE4zPDNizszN Mlr1V2FPT0WU
HEL MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNyOT6xOFkh|ryP MkPFV2FPT0WU
KINGS-1 NIHFcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nIO2lEPTB;M{GwMlY4PCEQvF2= NFjqWFdUSU6JRWK=
KY821 M2XUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ZXIZJUUN3ME2zN|YvPTl3IN88US=> Mn7IV2FPT0WU
MZ1-PC NFfkWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN2NT62NVgh|ryP M{DiXXNCVkeHUh?=
LS-411N MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN3ND62OkDPxE1? M3PHdXNCVkeHUh?=
SIG-M5 NELQUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN3OT63PFIh|ryP MoPrV2FPT0WU
HT NInrT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPDTWM2OD1|NkeuO|EyKM7:TR?= M4HLWHNCVkeHUh?=
HC-1 NGjPR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfGXIpKSzVyPUO2O{44QDdizszN MkKzV2FPT0WU
NCI-H1694 NGrGbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz1OFc1UUN3ME2zO|IvQTN2IN88US=> MVXTRW5ITVJ?
BB65-RCC NUW0[Hg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYR2ZKSzVyPUO3Ok4zPDVizszN NIDnZnZUSU6JRWK=
HAL-01 NFnnOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBTWM2OD1|N{muPFM5KM7:TR?= NVXMZW1xW0GQR1XS
ARH-77 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfPS49KSzVyPUO5OE4xODhizszN NUjaXmxIW0GQR1XS
MZ7-mel MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHFTWM2OD1|OUeuNlM{KM7:TR?= NGD0N5NUSU6JRWK=
SIMA NHjXWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13kNGlEPTB;NECzMlk{OyEQvF2= NH2wbnVUSU6JRWK=
DG-75 NVzIN2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD12MUWuOlk5KM7:TR?= NXLCdlN4W0GQR1XS
HUTU-80 NVW2TJRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ixSmlEPTB;NEG5MlE5PSEQvF2= M{PyeHNCVkeHUh?=
KNS-42 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC0TWM2OD12MkWuPFE2KM7:TR?= MlvkV2FPT0WU
SH-4 NWDOWG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TH[2lEPTB;NEK3MlU3PSEQvF2= NWjsOYYzW0GQR1XS
L-540 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXUTWM2OD12M{GuNFMyKM7:TR?= M3nYfnNCVkeHUh?=
NB10 NHHx[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR2MT6yN|Qh|ryP M1LtO3NCVkeHUh?=
ES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTR3Mj63OVMh|ryP MnXlV2FPT0WU
KMOE-2 NGX4PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHoTWM2OD12NU[uO|EyKM7:TR?= NX;ib4ViW0GQR1XS
MC116 NWC0ToxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TpfGlEPTB;NEW4MlEyPiEQvF2= MYXTRW5ITVJ?
RCC10RGB M2nkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[5cJFKSzVyPUS2NE4xODVizszN M1zxNXNCVkeHUh?=
RL95-2 NXfp[lZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPJTWM2OD12NkCuNlM4KM7:TR?= MWPTRW5ITVJ?
Raji NETaXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKe2ZKSzVyPUS2PE4yPDNizszN MoXmV2FPT0WU
CAS-1 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR5Mj6wO|Mh|ryP MUnTRW5ITVJ?
Calu-6 NY\helVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTR5NT6yOlUh|ryP MnLQV2FPT0WU
KG-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn4OlVbUUN3ME20O|gvPDRizszN MlT1V2FPT0WU
LB771-HNC NGjvVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTiV5ZKSzVyPUS4Nk4zOzJizszN NV;4[VN3W0GQR1XS
ACN MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrxRmdRUUN3ME20PVMvPTl7IN88US=> MmTtV2FPT0WU
KM12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCT45EUUN3ME20PVYvPTh7IN88US=> NEHLOJVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO <1 mg/mL
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID